Evidence review · from the 250-topic plan

SURMOUNT-1, reread: what the 20.9% trial actually established

The design, and why it was built this way

Published in NEJM in 2022, SURMOUNT-1 enrolled adults with obesity (BMI 30+, or 27+ with a weight-related condition), explicitly excluding diabetes — because the question was weight, cleanly. Everyone received lifestyle counseling; randomization added weekly tirzepatide at three maintenance doses or placebo for 72 weeks, with titration up the standard ladder. Three-to-one odds of receiving active drug, double-blind throughout — the design that makes the placebo arm's ~3% the honest baseline for what counseling alone buys in this population.

The dose-response that anchors everything

Average body-weight reduction: about 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, against roughly 3.1% on placebo. The staircase pattern matters as much as the peak: it demonstrated real pharmacological dose-response, it established 5 mg — the gentlest maintenance rung — as a ~15% therapy in its own right, and it's the reason "what dose will I need?" is a genuinely open clinical question rather than a foregone march to 15.

The threshold story the averages hide

Averages flatten distributions; the thresholds un-flatten them. Large majorities of treated participants cleared 5% (the old bar for "clinically meaningful"); at the top dose, over half reached 20% or more — bariatric-surgery territory from a weekly injection — while roughly a third of the 15 mg arm cleared 25%. Placebo cleared 20% about 3% of the time. When a program quotes you "up to" numbers, this distribution is what honest versions of that phrase are pointing at.

The extension that reframed the class

Participants with prediabetes were followed for roughly three years — and tirzepatide reduced progression to type 2 diabetes by about 94% versus placebo. That is prevention-scale evidence: the strongest argument on record that treating obesity pharmacologically treats the disease pipeline downstream of it, and a large part of why clinicians stopped tolerating the word "cosmetic."

The safety ledger

The bill was the class's usual currency: nausea, diarrhea, constipation, vomiting — mostly mild to moderate, concentrated during dose escalation, with discontinuation for adverse events in the mid-single digits across active arms. Serious events tracked the label's known list (gallbladder disease with rapid loss, rare pancreatitis, the rodent-derived thyroid C-cell warning). No new signal emerged; the trial's safety contribution was volume and duration, not surprise.

What the trial cannot say

Three honest boundaries. Individuals: averages are forecasts with wide error bars; some participants lost little. Durability: 72 weeks on therapy says nothing about after — that experiment is SURMOUNT-4, and its answer (about half regained within a year off) is the other half of this file. Product: the trial studied the approved product; compounded tirzepatide shares the intended molecule, not the trial certificate — no FDA review means no inherited proof of consistency, which is exactly the trade the compounded discount prices.

The money translation

Two numbers from this trial should shape shopping. First, 5 mg averaged ~15% — so a budget-driven, tolerability-driven middle dose is not a consolation prize, and programs that price you upward per rung are charging a toll the science doesn't require. Second, the doses that produced the famous averages are precisely where dose-tiered pricing peaks: the audited flat benchmark in our field runs $139/month at every rung ($1,668/year), while tiered rivals commonly add $80–$100/month by maintenance — roughly a quiet thousand dollars for the same staircase this trial climbed. The trial paid in nausea; don't also pay in tiers. The audited flat-rate file ↗

FAQ

How much weight did people lose in SURMOUNT-1?

Averages of about 15%, 19.5%, and 20.9% at tirzepatide 5, 10, and 15 mg over 72 weeks, versus ~3% on placebo — with over half of the top-dose arm losing 20% or more.

Did SURMOUNT-1 include people with diabetes?

No — it deliberately enrolled adults with obesity without diabetes; the diabetes program (SURPASS) ran separately, and the prediabetes subset's 3-year extension showed ~94% reduced progression to type 2 diabetes.

Is 5 mg tirzepatide effective?

Yes — ~15% average loss at 72 weeks, a result that would have led the field before this class arrived; the right maintenance dose is a tolerability-and-response decision, not a race to 15.

Does compounded tirzepatide have SURMOUNT-1's results?

It shares the intended active ingredient; the trial certificate — proof of safety, efficacy and consistency — belongs to the FDA-approved product studied.

Sources

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022.
• SURMOUNT-1 three-year prediabetes extension results, 2024–25 publications and presentations.
• Zepbound prescribing information — dosing, warnings, titration.
• SURMOUNT-4 (randomized withdrawal) for the durability boundary.
• Audited field pricing — the open dataset, confirmed 2026-08-14.